全文获取类型
收费全文 | 289246篇 |
免费 | 22961篇 |
国内免费 | 11084篇 |
专业分类
耳鼻咽喉 | 1685篇 |
儿科学 | 5294篇 |
妇产科学 | 3596篇 |
基础医学 | 31324篇 |
口腔科学 | 4026篇 |
临床医学 | 25993篇 |
内科学 | 43266篇 |
皮肤病学 | 2585篇 |
神经病学 | 19351篇 |
特种医学 | 12676篇 |
外国民族医学 | 18篇 |
外科学 | 33951篇 |
综合类 | 45335篇 |
现状与发展 | 42篇 |
一般理论 | 9篇 |
预防医学 | 19745篇 |
眼科学 | 3130篇 |
药学 | 35519篇 |
116篇 | |
中国医学 | 19217篇 |
肿瘤学 | 16413篇 |
出版年
2024年 | 488篇 |
2023年 | 4168篇 |
2022年 | 5853篇 |
2021年 | 12247篇 |
2020年 | 10678篇 |
2019年 | 9871篇 |
2018年 | 9807篇 |
2017年 | 10994篇 |
2016年 | 11595篇 |
2015年 | 10752篇 |
2014年 | 14594篇 |
2013年 | 19363篇 |
2012年 | 15722篇 |
2011年 | 18353篇 |
2010年 | 12995篇 |
2009年 | 12818篇 |
2008年 | 14288篇 |
2007年 | 15169篇 |
2006年 | 14499篇 |
2005年 | 12955篇 |
2004年 | 10821篇 |
2003年 | 9667篇 |
2002年 | 7853篇 |
2001年 | 7061篇 |
2000年 | 5914篇 |
1999年 | 4959篇 |
1998年 | 4107篇 |
1997年 | 4002篇 |
1996年 | 3616篇 |
1995年 | 3084篇 |
1994年 | 2895篇 |
1993年 | 2389篇 |
1992年 | 2202篇 |
1991年 | 1965篇 |
1990年 | 1727篇 |
1989年 | 1432篇 |
1988年 | 1332篇 |
1987年 | 1199篇 |
1986年 | 1081篇 |
1985年 | 1502篇 |
1984年 | 1196篇 |
1983年 | 875篇 |
1982年 | 930篇 |
1981年 | 788篇 |
1980年 | 741篇 |
1979年 | 588篇 |
1978年 | 398篇 |
1977年 | 344篇 |
1976年 | 343篇 |
1975年 | 228篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
101.
Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer-related mortality within the next decade, with limited effective treatment options and a dismal long-term prognosis for patients. Genomic profiling has not yet manifested clinical benefits for diagnosis, treatment or prognosis in PDAC, due to the lack of available tissues for sequencing and the confounding effects of low tumour cellularity in many biopsy specimens. Increasing focus is now turning to the use of minimally invasive liquid biopsies to enhance the characterisation of actionable PDAC tumour genomes. Circulating tumour DNA (ctDNA) is the most comprehensively studied liquid biopsy analyte in blood and can provide insight into the molecular profile and biological characteristics of individual PDAC tumours, in real-time and in advance of traditional imaging modalities. This can pave the way for identification of new therapeutic targets, novel risk variants and markers of tumour response, to supplement diagnostic screening and provide enhanced scrutiny in treatment stratification. In the roadmap towards the application of precision medicine for clinical management in PDAC, ctDNA analyses may serve a leading role in streamlining candidate biomarkers for clinical integration. In this review, we highlight recent developments in the use of ctDNA-based liquid biopsies for PDAC and provide new insights into the technical, analytical and biological challenges that must be overcome for this potential to be realised. 相似文献
102.
Rohi Shah Nomaan Sheikh Jitendra Mangwani Nicolette Morgan Hamidreza Khairandish 《Journal of Clinical Orthopaedics and Trauma》2021,12(1):138
Demographic projections for hip fragility fractures indicate a rising annual incidence by virtue of a multimorbid, ageing population with more noncommunicable diseases (NCDs). NCDs are characterised by slow progression and long duration ranging from ischaemic cardiovascular disease, cerebrovascular disease, diabetes, chronic obstructive pulmonary disease to various cancers. Management of this disease burden often involves commencing patients on oral anticoagulants to reduce the risk of thromboembolic events. The use of direct oral anticoagulants (DOACs) in clinical practice has increased due to their rapid onset of action, short half-life and predictable anticoagulant effects, without the need for routine monitoring. Safe and timely surgical intervention relies on reversal of anticoagulants. However, the lack of specific evidence-based guidelines for the perioperative management of patients on DOACs with hip fractures has proved challenging; in particular, the accessibility of DOAC-specific assays, justification of the cost-benefit ratio of targeted reversal agents and indications for neuraxial anaesthesia. This has led to potentially avoidable delays in surgical intervention. Following a literature review of the pharmacokinetic and pharmacodynamics of commonly used DOACs in our region including the role of surrogate markers, we propose a systematic, evidence-based guideline to the perioperative management of hip fractures DOACs. We believe this standardised protocol can be easily replicated between hospitals. We recommend that if patients are deemed suitable for a general anaesthesia, with satisfactory renal function, optimal surgical time should be 24 h following the last ingested dose of DOAC. 相似文献
103.
104.
105.
106.
107.
ABSTRACTThis work collates data from the analysis of complex mixtures analysed in STRmix during routine no-suspect volume crime work. It interrogates the upload rate for these types of mixtures and which component of the profile has been able to be interpreted for upload. The number of profiles giving multiple uploads and the amount of replicate PCR analysis has been collated. 相似文献
108.
目的 通过观察早产儿不同胎龄Toll样受体9(TLR9)的表达,探讨早产儿免疫功能低下的机制。方法 采集2010年7月至2014年6月在上海市嘉定区妇幼保健院产科出生的活产新生儿的脐血229份,按胎龄分为4组,28~31周组,31~34周组,34~37周组,≥37周组,采用流式细胞术和实时荧光定量PCR方法,分别检测其TLR9的蛋白和mRNA表达情况,了解其与胎龄之间的关系,并分析mRNA和蛋白表达间的相关性。结果 TLR9阳性细胞率在28~31周组,31~34周组,34~37周组,≥37周组分别为(15.93±6.23)%,(11.63±6.70)%,(13.66±6.88)%,(20.51±12.06)%;其在胎龄28~31周较高,至31~34周逐渐下降至最低,两组差异有统计学意义(P<0.05);34~37周后TLR9阳性细胞率表达逐渐升高,至≥37周达最高,两胎龄组比较,差异具有统计学意义(P<0.05)。31~37周间新生儿脐血TLR9阳性细胞率与胎龄呈正相关(r=0.273,P=0.006)。TLR9 mRNA表达在28~31周组,31~34周组,34~37周组,≥37周组分别为(4.95±3.44)%,(8.89±8.49)%,(13.91±10.92)%,(7.19±7.11)%;其在28~36周逐渐升高,与胎龄呈正相关(r=0.355,P< 0.001)。≥37周TLR9 mRNA表达量下降,该值虽高于28~31周,但差异无统计学意义(P>0.05)。相关性分析表明,同胎龄时期同样本新生儿的TLR9 mRNA和TLR9阳性细胞率之间存在负相关(r=-0.227,P=0.011)。结论 TLR9阳性细胞率和TLR9 mRNA表达在不同胎龄组新生儿间有差异,TLR9阳性细胞率表达在31~37周间随着胎龄的增加而增加,TLR9 mRNA在28~36周间随着胎龄的增加而增加。 相似文献
109.
目的 探讨肝动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)术前天冬氨酸氨基转移酶与淋巴细胞比值(aspartate aminotransferase to lymphocyte ratio index,ALRI)在原发性肝癌并门脉癌栓(primary liver cancer-portal vein tumor thrombosis,PLC-PVTT)患者预后预测中的价值。方法 选取2013年11月21日至2018年8月22日于广西医科大学附属肿瘤医院接受TACE治疗的175例PLC-PVTT患者为研究对象。采用时间依赖性ROC曲线确定ALRI的最佳临界值。采用Cox 回归模型分析总生存期(overall survival,OS)的独立预测因素,Kaplan-Meier法计算生存率。结果 ROC曲线显示,ALRI的最佳临界值为49.37,对应曲线下面积为0.71。Kaplan-Meier分析显示,ALRI>49.37的患者OS较ALRI≤49.37的患者短(P=0.003)。Cox 回归分析结果显示,ALRI>49.37、行1次以上TACE治疗、Child-Pugh分级B级、凝血酶原时间≥13 s是患者TACE术后OS的独立危险因素(均P<0.05)。结论 TACE术前ALRI>49.37是PLC-PVTT患者OS的独立危险因素。 相似文献
110.